RxSight Affirms FY2026 Sales Guidance of $120.000M-$135.000M vs $129.182M Est

RxSight, Inc.

RxSight, Inc.

RXST

0.00

2026 Guidance: The company's 2026 financial guidance is as follows:

  • Revenue of $120 to $135 million, in-line with previous guidance
  • Gross margin of 70% to 72%, in-line with previous guidance
  • Operating expenses expected to be at the high-end of previous $150 to $160 million range
  • Non-cash stock-based compensation expense of $30 to $32 million, in-line with previous guidance
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.